Skip to main content

Bacteremia

6
Pipeline Programs
11
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
3
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
1
DaptomycinPhase 41 trial
Daptomycin for InjectionPhase 2
Active Trials
NCT02660346Completed40Est. Jan 2018
Pfizer
PfizerNEW YORK, NY
1 program
1
Cefazolin IVPhase 31 trial
Active Trials
NCT00108433Terminated61Est. Sep 2006
TauroPharm
TauroPharmGermany - Waldbüttelbrunn
1 program
1
TaurolockPhase 31 trial
Active Trials
NCT00735813Completed129Est. Sep 2012
Cumberland Pharmaceuticals
1 program
1
TelavancinPhase 31 trial
Active Trials
NCT02208063Terminated121Est. Apr 2018
MSD
MSDIreland - Ballydine
1 program
1
Daptomycin for InjectionPhase 21 trial
Active Trials
NCT03643952Completed18Est. Apr 2020
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
Blood culture identification panelN/A1 trial
Active Trials
NCT05314816Completed479Est. Nov 2022
Molzym
MolzymGermany - Bremen
1 program
Fast Assay for Pathogen Identification and CharacterizationN/A1 trial
Active Trials
NCT03841162Completed1,957Est. Apr 2020
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
FilmArray testingN/A1 trial
Active Trials
NCT01898208Completed743Est. Aug 2014
Shield Therapeutics
Shield TherapeuticsMA - Wellesley
1 program
Iodine tinctureN/A1 trial
Active Trials
NCT01216761Completed3,879Est. Nov 2009
ExThera Medical
ExThera MedicalCA - Martinez
1 program
Seraph 100 FilterN/A1 trial
Active Trials
NCT02914132Completed15Est. Jun 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sharp TherapeuticsDaptomycin
Cumberland PharmaceuticalsTelavancin
TauroPharmTaurolock
PfizerCefazolin IV
MSDDaptomycin for Injection
Colorado TherapeuticsBlood culture identification panel
MolzymFast Assay for Pathogen Identification and Characterization
ExThera MedicalSeraph 100 Filter
Allergy TherapeuticsFilmArray testing
Shield TherapeuticsIodine tincture

Clinical Trials (10)

Total enrollment: 7,442 patients across 10 trials

NCT02660346Sharp TherapeuticsDaptomycin

IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB

Start: Nov 2015Est. completion: Jan 201840 patients
Phase 4Completed
NCT02208063Cumberland PharmaceuticalsTelavancin

A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial

Start: Dec 2014Est. completion: Apr 2018121 patients
Phase 3Terminated
NCT00735813TauroPharmTaurolock

Taurolidine Lock Solution in the Prevention of Catheter Related Bacteremia

Start: Apr 2008Est. completion: Sep 2012129 patients
Phase 3Completed
NCT00108433PfizerCefazolin IV

Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections

Start: Sep 2005Est. completion: Sep 200661 patients
Phase 3Terminated
NCT03643952MSDDaptomycin for Injection

Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)

Start: Dec 2018Est. completion: Apr 202018 patients
Phase 2Completed
NCT05314816Colorado TherapeuticsBlood culture identification panel

Rapid Blood Culture Identification Panel in Pediatric Patients in Guatemala

Start: Apr 2022Est. completion: Nov 2022479 patients
N/ACompleted
NCT03841162MolzymFast Assay for Pathogen Identification and Characterization

Fast Assay for Pathogen Identification and Characterization

Start: Feb 2019Est. completion: Apr 20201,957 patients
N/ACompleted
NCT02914132ExThera MedicalSeraph 100 Filter

Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis

Start: Feb 2016Est. completion: Jun 201815 patients
N/ACompleted
NCT01898208Allergy TherapeuticsFilmArray testing

Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures

Start: Aug 2013Est. completion: Aug 2014743 patients
N/ACompleted
NCT01216761Shield TherapeuticsIodine tincture

A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions

Start: May 2008Est. completion: Nov 20093,879 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.